

Accepted Manuscript

Iminoenamine based novel androgen receptor antagonist exhibited anti-prostate cancer activity in androgen independent prostate cancer cells through inhibition of AKT pathway

S. Divakar, K. Saravanan, P. Karthikeyan, R. Elencheran, S. Kabilan, K.K. Balasubramanian, Rajlakshmi Devi, J. Kotoky, M. Ramanathan

PII: S0009-2797(16)30524-5

DOI: [10.1016/j.cbi.2017.07.023](https://doi.org/10.1016/j.cbi.2017.07.023)


Reference: CBI 8065

To appear in: *Chemico-Biological Interactions*

Received Date: 3 November 2016

Revised Date: 21 June 2017

Accepted Date: 26 July 2017



Please cite this article as: S. Divakar, K. Saravanan, P. Karthikeyan, R. Elencheran, S. Kabilan, K.K. Balasubramanian, R. Devi, J. Kotoky, M. Ramanathan, Iminoenamine based novel androgen receptor antagonist exhibited anti-prostate cancer activity in androgen independent prostate cancer cells through inhibition of AKT pathway, *Chemico-Biological Interactions* (2017), doi: 10.1016/j.cbi.2017.07.023.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Iminoenamine based novel androgen receptor antagonist exhibited anti-prostate cancer activity in androgen independent prostate cancer cells through inhibition of AKT pathway

S. Divakar^a, K. Saravanan^b, P. Karthikeyan^c, R. Elencheran^e, S. Kabilan^b, K. K. Balasubramanian^{c, f}, Rajlakshmi Devi^d, J. Kotoky^e, M. Ramanathan^{a, *}

^aDepartment of Pharmacology, PSG College of Pharmacy, Coimbatore, Tamil Nadu, India.

^bDepartment of Chemistry, Annamalai University, Chidambaram, Tamil Nadu, India.

^cShasun Research Centre, Kellakottaiyur, Chennai, Tamil Nadu, India.

^dDepartment of Life Sciences, IASST, Guwahati, Assam, India.

^eDepartment of Chemistry, IASST, Guwahati, Assam, India.

^fPresent affiliation, Department of Biotechnology, IIT Madras, Tamil Nadu, India

***Corresponding author**

Dr. M. Ramanathan, Professor,

Principal,

PSG College of Pharmacy,

Peelamedu,

Coimbatore - 04.

Email: muthiah.in@gmail.com

Phone: +918870009199

Abstract

Treatment by androgen receptor (AR) antagonists is one of the regimens for prostate cancer. The prolonged treatment with AR antagonist leads to the expression of point mutation in the ligand binding domain of the AR. This point mutation causes resistance to AR

Download English Version:

<https://daneshyari.com/en/article/5559259>

Download Persian Version:

<https://daneshyari.com/article/5559259>

[Daneshyari.com](https://daneshyari.com)